HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Cullinan Oncology (NASDAQ:CGEM) and maintained a price target of $49.
July 07, 2023 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cullinan Oncology's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $49.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $49 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100